Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Endokrynologia Polska
MENU
Shortcuts Submit an article Author Guidelines Polish Society of Endocrinology Reviewers 2023 Redeem voucher

open access

Vol 69, No 4 (2018)
Review paper
Submitted: 2017-09-02
Accepted: 2017-09-07
Published online: 2018-08-21
View PDF Download PDF file
Get Citation

The content of this article is also available in the following languages:
Polski

Pharmacotherapy of obesity — state of the art

Beata Matyjaszek-Matuszek1, Aneta Szafraniec1, Dominik Porada1
DOI: 10.5603/EP.2018.0048
·
Pubmed: 30209803
·
Endokrynol Pol 2018;69(4):448-466.
Affiliations
  1. Medical University of Lublin

open access

Vol 69, No 4 (2018)
Reviews — Postgraduate Education
Submitted: 2017-09-02
Accepted: 2017-09-07
Published online: 2018-08-21

Abstract

Obesity, which affects about 13% of the world population, results in significant deterioration of health and serious clinical, mainly meta­bolic and cardiovascular complications. Although the basis of therapeutic treatment is behavioural treatment, often non-pharmacological effects do not produce the desired effect. Currently there are several drugs with a safe action profile that improve the effect of treatment (5–10% weight reduction). The aim of the paper is to present the potential of modern pharmacotherapy in the treatment of obesity, in terms of mechanism of action, efficacy, and side effects, in order to individualise therapy. The drugs already registered include substances with a variety of mechanisms of action, including phentermine, orlistat, lorcaserin, and liraglutide. Compounded preparations (phenter­mine/topiramate, naltrexone SR/bupropion SR) are also available, which, by using low doses of active substances, have beneficial effects while reducing side effects. In addition, several drugs used to treat diabetes, such as metformin, SGLT2 inhibitors, GLP-1 agonists, and pramlintide, promote weight loss, although their use is reserved for diabetics, especially type 2 patients. Regarding the current alarm­ing epidemiological data there is a need for intensive prevention and treatment of obesity as well as the development of a new form of pharmacotherapy (new substances and treatment regimens) to develop effective, safe, and, above all, long-term effective therapy for the treatment of obesity.

Abstract

Obesity, which affects about 13% of the world population, results in significant deterioration of health and serious clinical, mainly meta­bolic and cardiovascular complications. Although the basis of therapeutic treatment is behavioural treatment, often non-pharmacological effects do not produce the desired effect. Currently there are several drugs with a safe action profile that improve the effect of treatment (5–10% weight reduction). The aim of the paper is to present the potential of modern pharmacotherapy in the treatment of obesity, in terms of mechanism of action, efficacy, and side effects, in order to individualise therapy. The drugs already registered include substances with a variety of mechanisms of action, including phentermine, orlistat, lorcaserin, and liraglutide. Compounded preparations (phenter­mine/topiramate, naltrexone SR/bupropion SR) are also available, which, by using low doses of active substances, have beneficial effects while reducing side effects. In addition, several drugs used to treat diabetes, such as metformin, SGLT2 inhibitors, GLP-1 agonists, and pramlintide, promote weight loss, although their use is reserved for diabetics, especially type 2 patients. Regarding the current alarm­ing epidemiological data there is a need for intensive prevention and treatment of obesity as well as the development of a new form of pharmacotherapy (new substances and treatment regimens) to develop effective, safe, and, above all, long-term effective therapy for the treatment of obesity.

Full Text:

View PDF Download PDF file
Get Citation

Keywords

obesity, pharmacotherapy, phentermine, orlistat, lorcaserin, phentermine/topiramate, naltrexone SR/bupropion SR, antidiabetic drugs

About this article
Title

Pharmacotherapy of obesity — state of the art

Journal

Endokrynologia Polska

Issue

Vol 69, No 4 (2018)

Article type

Review paper

Pages

448-466

Published online

2018-08-21

Page views

5117

Article views/downloads

3699

DOI

10.5603/EP.2018.0048

Pubmed

30209803

Bibliographic record

Endokrynol Pol 2018;69(4):448-466.

Keywords

obesity
pharmacotherapy
phentermine
orlistat
lorcaserin
phentermine/topiramate
naltrexone SR/bupropion SR
antidiabetic drugs

Authors

Beata Matyjaszek-Matuszek
Aneta Szafraniec
Dominik Porada

References (81)
  1. NCD Risk Factor Collaboration (NCD-RisC). Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19·2 million participants. Lancet. 2016; 387(10026): 1377–1396.
    CrossRefPubMed
  2. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser. 2000; 894: i–xii, 1.
    PubMed
  3. Pollack A. [2013]. A.M.A. Recognizes obesity as a disease, [online]. http://www.nytimes.com/2013/06/19/business/ama-recognizes-obesity-as-a-disease.html (2017, May 22).
  4. Wohlfahrt-Veje C, Tinggaard J, Winther K, et al. Body fat throughout childhood in 2647 healthy Danish children: agreement of BMI, waist circumference, skinfolds with dual X-ray absorptiometry. Eur J Clin Nutr. 2014; 68(6): 664–670.
    CrossRefPubMed
  5. Soto González AS, Bellido D, Buño MM, et al. Predictors of the metabolic syndrome and correlation with computed axial tomography. Nutrition. 2007; 23(1): 36–45.
    CrossRefPubMed
  6. Lee K, Lee S, Kim YJ, et al. Waist circumference, dual-energy X-ray absortiometrically measured abdominal adiposity, and computed tomographically derived intra-abdominal fat area on detecting metabolic risk factors in obese women. Nutrition. 2008; 24(7-8): 625–631.
    CrossRefPubMed
  7. Reho JJ, Rahmouni K. Oxidative and inflammatory signals in obesity-associated vascular abnormalities. Clin Sci (Lond). 2017; 131(14): 1689–1700.
    CrossRefPubMed
  8. Marseglia L, Manti S, D'Angelo G, et al. Oxidative stress in obesity: a critical component in human diseases. Int J Mol Sci. 2014; 16(1): 378–400.
    CrossRefPubMed
  9. Ha H, Han C, Kim B. Can Obesity Cause Depression? A Pseudo-panel Analysis. J Prev Med Public Health. 2017; 50(4): 262–267.
    CrossRefPubMed
  10. Luppino FS, de Wit LM, Bouvy PF, et al. Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies. Arch Gen Psychiatry. 2010; 67(3): 220–229.
    CrossRefPubMed
  11. Witkowska-Sędek E, Kucharska A, Rumińska M, et al. Thyroid dysfunction in obese and overweight children. Endokrynol Pol. 2017; 68(1): 54–60.
    CrossRefPubMed
  12. Flegal KM, Kruszon-Moran D, Carroll MD, et al. Trends in Obesity Among Adults in the United States, 2005 to 2014. JAMA. 2016; 315(21): 2284–2291.
    CrossRefPubMed
  13. Global Food Security Index .[2016]. [online]. http://www.dupont.com/forms/dupont-food-security.html (2017, May 22).
  14. WHO. [2015]. The challenge of obesity in the WHO European Region. [online]. http://www.euro.who.int/__data/assets/pdf_file/0018/102384/fs1305e.pdf (2017, May 22).
  15. Podolec P, Karch I, Pająk A, et al. Przegląd polskich badań epidemiologicznych w kardiologii. Kardiol Pol. 2006; 64: 1031–1037.
  16. Instytut Kardiologii. Ogólnopolskie i regionalne rozpowszechnienie głównych czynników ryzyka układu sercowo-naczyniowego. Wyniki ogólnopolskiego badania stanu zdrowia ludności program WOBASZ. Kardiol Pol. 2005; 63(Suppl. 4): 614–685.
  17. Broda G, Rywik S. Wieloośrodkowe ogólnopolskie badanie zdrowia ludności – projekt WOBASZ. Zdefiniowanie problemu oraz cele badania. Kardiol Pol. 2005; 63(Suppl. 4): 601–604.
  18. Drygas W, Niklas A, Piwońska A, et al. Wieloośrodkowe Ogólnopolskie Badanie Stanu Zdrowia Ludności (badanie WOBASZ II): założenia, metody i realizacja. Kardiologia Polska. 2016; 74(7): 681–690.
    CrossRef
  19. Lindstrom J, Louheranta A, Mannelin M, et al. The Finnish Diabetes Prevention Study (DPS): Lifestyle intervention and 3-year results on diet and physical activity. Diabetes Care. 2003; 26(12): 3230–3236.
    CrossRef
  20. Look AHEAD Research Group. Eight-year weight losses with an intensive lifestyle intervention: the look AHEAD study. Obesity (Silver Spring). 2014; 22(1): 5–13.
    CrossRefPubMed
  21. Apovian CM, Aronne LJ, Bessesen DH, et al. Endocrine Society. Pharmacological management of obesity: an endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015; 100(2): 342–362.
    CrossRefPubMed
  22. Golzarand M, Toolabi K, Farid R. The bariatric surgery and weight losing: a meta-analysis in the long- and very long-term effects of laparoscopic adjustable gastric banding, laparoscopic Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy on weight loss in adults. Surg Endosc. 2017; 31(11): 4331–4345.
    CrossRefPubMed
  23. Shoar S, Mahmoudzadeh H, Naderan M, et al. Long-Term Outcome of Bariatric Surgery in Morbidly Obese Adolescents: a Systematic Review and Meta-Analysis of 950 Patients with a Minimum of 3 years Follow-Up. Obes Surg. 2017; 27(12): 3110–3117.
    CrossRefPubMed
  24. Fernández-Soto ML, Martín-Leyva A, González-Jiménez A, et al. Remission of type 2 diabetes mellitus after bariatric surgery - comparison between procedures. Endokrynol Pol. 2017; 68(1): 18–25.
    CrossRefPubMed
  25. Krentz AJ, Fujioka K, Hompesch M. Evolution of pharmacological obesity treatments: focus on adverse side-effect profiles. Diabetes Obes Metab. 2016; 18(6): 558–570.
    CrossRefPubMed
  26. Bray GA, Ryan DH. Medical therapy for the patient with obesity. Circulation. 2012; 125(13): 1695–1703.
    CrossRefPubMed
  27. Haddock CK, Poston WSC, Dill PL, et al. Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials. Int J Obes Relat Metab Disord. 2002; 26(2): 262–273.
    CrossRefPubMed
  28. Jick H, Vasilakis C, Weinrauch LA, et al. A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation. N Engl J Med. 1998; 339(11): 719–724.
    CrossRefPubMed
  29. Ryder JR, Kaizer A, Rudser KD, et al. Effect of phentermine on weight reduction in a pediatric weight management clinic. Int J Obes (Lond). 2017; 41(1): 90–93.
    CrossRefPubMed
  30. Khera R, Murad MH, Chandar AK, et al. Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis. JAMA. 2016; 315(22): 2424–2434.
    CrossRefPubMed
  31. Torgerson JS, Hauptman J, Boldrin MN, et al. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004; 27(1): 155–161.
    PubMed
  32. Hodkinson A, Gamble C, Smith CT. Reporting of harms outcomes: a comparison of journal publications with unpublished clinical study reports of orlistat trials. Trials. 2016; 17(1): 207.
    CrossRefPubMed
  33. Smith SR, Weissman NJ, Anderson CM, et al. Behavioral Modification and Lorcaserin for Overweight and Obesity Management (BLOOM) Study Group. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med. 2010; 363(3): 245–256.
    CrossRefPubMed
  34. O'Neil PM, Smith SR, Weissman NJ, et al. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity (Silver Spring). 2012; 20(7): 1426–1436.
    CrossRefPubMed
  35. Centers for Disease Control and Prevention (CDC). Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine: U.S. Department of Health and Human Services interim public health recommendations, November 1997. MMWR Morb Mortal Wkly Rep. 1997; 46(45): 1061–1066.
    PubMed
  36. Richard D, Ferland J, Lalonde J, et al. Influence of topiramate in the regulation of energy balance. Nutrition. 2000; 16(10): 961–966.
    PubMed
  37. Scozzafava A, Supuran CT, Carta F. Antiobesity carbonic anhydrase inhibitors: a literature and patent review. Expert Opin Ther Pat. 2013; 23(6): 725–735.
    CrossRefPubMed
  38. Rosenfeld WE. Topiramate: a review of preclinical, pharmacokinetic, and clinical data. Clin Ther. 1997; 19(6): 1294–1308.
    PubMed
  39. Richard D, Picard F, Lemieux C, et al. The effects of topiramate and sex hormones on energy balance of male and female rats. Int J Obes Relat Metab Disord. 2002; 26(3): 344–353.
    CrossRefPubMed
  40. Gadde KM, Pritham Raj Y. Pharmacotherapy of Obesity: Clinical Trials to Clinical Practice. Curr Diab Rep. 2017; 17(5): 34.
    CrossRefPubMed
  41. Garvey WT, Ryan DH, Look M, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr. 2012; 95(2): 297–308.
    CrossRefPubMed
  42. Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet. 2011; 377(9774): 1341–1352.
    CrossRefPubMed
  43. Jordan J, Astrup A, Engeli S, et al. Cardiovascular effects of phentermine and topiramate: a new drug combination for the treatment of obesity. J Hypertens. 2014; 32(6): 1178–1188.
    CrossRefPubMed
  44. Aronne LJ, Wadden TA, Peterson C, et al. Evaluation of phentermine and topiramate versus phentermine/topiramate extended-release in obese adults. Obesity (Silver Spring). 2013; 21(11): 2163–2171.
    CrossRefPubMed
  45. Halpern B, Mancini MC. Safety assessment of combination therapies in the treatment of obesity: focus on naltrexone/bupropion extended release and phentermine-topiramate extended release. Expert Opin Drug Saf. 2017; 16(1): 27–39.
    CrossRefPubMed
  46. Finkelstein EA, Kruger E, Karnawat S. Cost-Effectiveness Analysis of Qsymia for Weight Loss. PharmacoEconomics. 2014; 33(7): 699–706.
    CrossRef
  47. Berg BJ, Pettinati HM, Volpicelli JR. A risk-benefit assessment of naltrexone in the treatment of alcohol dependence. Drug Saf. 1996; 15(4): 274–282.
    PubMed
  48. Lobmaier P, Kornør H, Kunøe N, et al. Sustained-release naltrexone for opioid dependence. Cochrane Database Syst Rev. 2008(2): CD006140.
    CrossRefPubMed
  49. Carroll FI, Blough BE, Mascarella SW, et al. Bupropion and bupropion analogs as treatments for CNS disorders. Adv Pharmacol. 2014; 69: 177–216.
    CrossRefPubMed
  50. Gadde KM, Parker CB, Maner LG, et al. Bupropion for weight loss: an investigation of efficacy and tolerability in overweight and obese women. Obes Res. 2001; 9(9): 544–551.
    CrossRefPubMed
  51. Verpeut JL, Bello NT. Drug safety evaluation of naltrexone/bupropion for the treatment of obesity. Expert Opin Drug Saf. 2014; 13(6): 831–841.
    CrossRefPubMed
  52. Billes SK, Sinnayah P, Cowley MA. Naltrexone/bupropion for obesity: an investigational combination pharmacotherapy for weight loss. Pharmacol Res. 2014; 84: 1–11.
    CrossRefPubMed
  53. Apovian CM, Aronne L, Rubino D, et al. COR-II Study Group. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity (Silver Spring). 2013; 21(5): 935–943.
    CrossRefPubMed
  54. Wadden TA, Foreyt JP, Foster GD, et al. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity (Silver Spring). 2011; 19(1): 110–120.
    CrossRefPubMed
  55. Nissen SE, Wolski KE, Prcela L, et al. Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors: A Randomized Clinical Trial. JAMA. 2016; 315(10): 990–1004.
    CrossRefPubMed
  56. Fujioka K, Plodkowski R, O'Neil PM, et al. The relationship between early weight loss and weight loss at 1 year with naltrexone ER/bupropion ER combination therapy. Int J Obes (Lond). 2016; 40(9): 1369–1375.
    CrossRefPubMed
  57. Pi-Sunyer X, Astrup A, Fujioka K, et al. SCALE Obesity and Prediabetes NN8022-1839 Study Group. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015; 373(1): 11–22.
    CrossRefPubMed
  58. Flint A, Raben A, Ersbøll AK, et al. The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity. Int J Obes Relat Metab Disord. 2001; 25(6): 781–792.
    CrossRefPubMed
  59. Astrup A, Carraro R, Finer N, et al. NN8022-1807 Investigators. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes (Lond). 2012; 36(6): 843–854.
    CrossRefPubMed
  60. Marso SP, Daniels GH, Brown-Frandsen K, et al. LEADER Steering Committee, LEADER Trial Investigators. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016; 375(4): 311–322.
    CrossRefPubMed
  61. Davies MJ, Bergenstal R, Bode B, et al. NN8022-1922 Study Group. Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial. JAMA. 2015; 314(7): 687–699.
    CrossRefPubMed
  62. Pi-Sunyer X, Astrup A, Fujioka K, et al. SCALE Obesity and Prediabetes NN8022-1839 Study Group. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015; 373(1): 11–22.
    CrossRefPubMed
  63. Steinberg WM, Rosenstock J, Wadden TA, et al. Impact of Liraglutide on Amylase, Lipase, and Acute Pancreatitis in Participants With Overweight/Obesity and Normoglycemia, Prediabetes, or Type 2 Diabetes: Secondary Analyses of Pooled Data From the SCALE Clinical Development Program. Diabetes Care. 2017; 40(7): 839–848.
    CrossRefPubMed
  64. Knowler WC, Barrett-Connor E, Fowler SE, et al. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002; 346(6): 393–403.
    CrossRefPubMed
  65. Malin SK, Kashyap SR. Effects of metformin on weight loss: potential mechanisms. Curr Opin Endocrinol Diabetes Obes. 2014; 21(5): 323–329.
    CrossRefPubMed
  66. Scheen AJ. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs. 2015; 75(1): 33–59.
    CrossRefPubMed
  67. Pinto L, Rados D, Remonti L, et al. Efficacy of SGLT2 inhibitors in glycemic control, weight loss and blood pressure reduction: a systematic review and meta-analysis. Diabetol Metab Syndr. 2015; 7(Suppl 1): A58.
    CrossRef
  68. Zinman B, Wanner C, Lachin JM, et al. EMPA-REG OUTCOME Investigators. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015; 373(22): 2117–2128.
    CrossRefPubMed
  69. Garber AJ. Long-acting glucagon-like peptide 1 receptor agonists: a review of their efficacy and tolerability. Diabetes Care. 2011; 34 Suppl 2: S279–S284.
    CrossRefPubMed
  70. Buse JB, Rosenstock J, Sesti G, et al. LEAD-6 Study Group. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009; 374(9683): 39–47.
    CrossRefPubMed
  71. Hoogwerf BJ, Doshi KB, Diab D. Pramlintide, the synthetic analogue of amylin: physiology, pathophysiology, and effects on glycemic control, body weight, and selected biomarkers of vascular risk. Vasc Health Risk Manag. 2008; 4(2): 355–362.
    PubMed
  72. Aronne L, Fujioka K, Aroda V, et al. Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: a phase 2, randomized, placebo-controlled, dose-escalation study. J Clin Endocrinol Metab. 2007; 92(8): 2977–2983.
    CrossRefPubMed
  73. Smith SR, Aronne LJ, Burns CM, et al. Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity. Diabetes Care. 2008; 31(9): 1816–1823.
    CrossRefPubMed
  74. The Endocrine Society. [2014] Hydrogel capsule, Gelesis100, reduces weight in overweight and obese subjects, [online]. https://www.eurekalert.org/pub_releases/2014-06/tes-hcg062314.php (2017, May 22).
  75. Bryson A, de la Motte S, Dunk C. Reduction of dietary fat absorption by the novel gastrointestinal lipase inhibitor cetilistat in healthy volunteers. Br J Clin Pharmacol. 2009; 67(3): 309–315.
    CrossRefPubMed
  76. Kopelman P, Bryson A, Hickling R, et al. Cetilistat (ATL-962), a novel lipase inhibitor: a 12-week randomized, placebo-controlled study of weight reduction in obese patients. Int J Obes (Lond). 2007; 31(3): 494–499.
    CrossRefPubMed
  77. Gadde KM, Yonish GM, Foust MS, et al. Combination therapy of zonisamide and bupropion for weight reduction in obese women: a preliminary, randomized, open-label study. J Clin Psychiatry. 2007; 68(8): 1226–1229.
    PubMed
  78. Aronne LJ, Halseth AE, Burns CM, et al. Enhanced weight loss following coadministration of pramlintide with sibutramine or phentermine in a multicenter trial. Obesity (Silver Spring). 2010; 18(9): 1739–1746.
    CrossRefPubMed
  79. Frías JP, Guja C, Hardy E, et al. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol. 2016; 4(12): 1004–1016.
    CrossRefPubMed
  80. Lundkvist P, Pereira MJ, Katsogiannos P, et al. Dapagliflozin once daily plus exenatide once weekly in obese adults without diabetes: Sustained reductions in body weight, glycaemia and blood pressure over 1 year. Diabetes Obes Metab. 2017; 19(9): 1276–1288.
    CrossRefPubMed
  81. Hollander P, Bays HE, Rosenstock J, et al. Coadministration of Canagliflozin and Phentermine for Weight Management in Overweight and Obese Individuals Without Diabetes: A Randomized Clinical Trial. Diabetes Care. 2017; 40(5): 632–639.
    CrossRefPubMed

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą jest  VM Media Group sp. z o.o., Grupa Via Medica, ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl